Cargando…

COVID-19 in patients with chronic myeloid leukaemia on tyrosine kinase inhibitor therapy: a Honduran observational study

INTRODUCTION: In the earliest cases of COVID-19, a higher percentage of severe and fatal cases was observed in patients with cancer, including those with haematological malignancies. However, patients with chronic myeloid leukaemia (CML) had better prognoses, suggesting that tyrosine kinase inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fajardoa, Carlos J, Cálixb, Eda Sofía, Mojicac, Rafael, Duarted, Flora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2022
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934964/ https://www.ncbi.nlm.nih.gov/pubmed/36819815 http://dx.doi.org/10.3332/ecancer.2022.1481

Ejemplares similares

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
por: Rychter, Anna, et al.
Publicado: (2017)

Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
por: Lindström, H. Jonathan G., et al.
Publicado: (2019)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
por: Clark, Richard E.
Publicado: (2019)

Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients
por: Allegra, Sarah, et al.
Publicado: (2023)

Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.
por: McMullan, RR, et al.
Publicado: (2019)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study): study protocol for a prospective, multicentre, single-arm trial
por: Djodikromo, Melissa F, et al.
Publicado: (2023)

The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia
por: Crisan, AM, et al.
Publicado: (2015)

Combination of curaxin and tyrosine kinase inhibitors display enhanced killing of primitive Chronic Myeloid Leukaemia cells
por: Pearson, Stella, et al.
Publicado: (2022)

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors
por: Nishiyama-Fujita, Yuriko, et al.
Publicado: (2022)

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
por: Kloth, J S L, et al.
Publicado: (2015)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
por: Carracedo, Miguel, et al.
Publicado: (2020)

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib
por: G. Lindström, H. Jonathan, et al.
Publicado: (2020)

Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies
por: Hewison, Ann, et al.
Publicado: (2020)

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
por: Harrington, Patrick, et al.
Publicado: (2022)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2017)

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
por: Ghatalia, P, et al.
Publicado: (2015)

Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol
por: Balakumaran, Janatani, et al.
Publicado: (2019)

Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia
por: Jiang, Liling, et al.
Publicado: (2022)

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
por: Beuselinck, B, et al.
Publicado: (2012)

Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor
por: Ono, Takaaki, et al.
Publicado: (2020)

Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors
por: Piekarska, Agnieszka, et al.
Publicado: (2016)

Human papillomavirus infection in honduran women with normal cytology
por: Tábora, N., et al.
Publicado: (2009)

Valorization of Honduran Agro-Food Waste to Produce Bioplastics
por: Castro-Criado, Daniel, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022)

S158: EFFICACY OF LOW-DOSE TYROSINE KINASE INHIBITOR THERAPY AFTER ACHIEVING MAJOR MOLECULAR RESPONSE IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA
por: LI, Zongru, et al.
Publicado: (2023)

PB1978: PATIENT-CENTREDNESS IS PIVOTAL IN A PROSPECTIVE DOSE REDUCTION TRIAL OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
por: Djodikromo, Melissa, et al.
Publicado: (2023)

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
por: Boss, D S, et al.
Publicado: (2012)

HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients
por: Zhao, X-Y, et al.
Publicado: (2014)

Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations
por: Glauche, I, et al.
Publicado: (2012)

Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors—A Single-Centre Retrospective Study
por: Varga, Andreea, et al.
Publicado: (2020)

A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia
por: Martín Roldán, Alicia, et al.
Publicado: (2023)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Interleukin-10 and soil-transmitted helminth infections in Honduran children
por: Sanchez, Ana Lourdes, et al.
Publicado: (2015)

Social behaviour and vocalizations of the tent-roosting Honduran white bat
por: Fernandez, Ahana Aurora, et al.
Publicado: (2021)

Psychometric properties of the Spanish version of the Flourishing Scale in the Honduran population
por: Landa-Blanco, Miguel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7fi2dt17mf5f8g6tpf6snc1d3n